Alumis Closes $259M Series B Round to Accelerate Next-Generation Precision Immunotherapy Advances

Alumis is proud to announce a major milestone as it successfully raised $259,000,000 in its latest funding round. This significant infusion of capital is a testament to the confidence investors have in Alumis’ revolutionary approach to treating immune-mediated diseases. At Alumis, our mission is to dramatically enhance the quality of life for patients by replacing traditional broad immunosuppression with precision-targeted therapies that offer hope for those who have long cycled through treatments with limited success. With this new funding, Alumis is well-positioned to accelerate its innovative pipeline, built on powerful data analytics and a holistic drug development strategy, to deliver therapies that address immune dysfunction with unparalleled accuracy. The capital will be dedicated to advancing our current research programs, optimizing our precision medicine platform, and expanding our team of seasoned professionals who are at the forefront of immunology and therapeutic development. By leveraging insights from cutting-edge data, Alumis is committed to identifying the right target, the right molecule, and the right patient, ultimately aiming for optimized outcomes that minimize life-limiting side effects while effectively combating the debilitating impacts of disease. Incubated by Foresite Labs, our company is driven by a passion to transform patient care and create a future where targeted treatments redefine how immune-mediated conditions are managed. This investment is not only a financial boost but a clear signal that our integrated approach to research and drug development is poised to make a lasting impact on patient lives, opening new avenues for treatments that were once only a distant dream.